Palvella Therapeutics, Inc.
PVLA
$120.57
-$5.22-4.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.52M | 4.18M | 3.65M | 4.13M | 3.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.86M | 11.30M | 10.18M | 9.25M | 7.87M |
| Operating Income | -14.86M | -11.30M | -10.18M | -9.25M | -7.87M |
| Income Before Tax | -15.77M | -12.71M | -11.35M | -9.47M | -8.19M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.77M | -12.71M | -11.35M | -9.47M | -8.19M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.77M | -12.71M | -11.35M | -9.47M | -8.19M |
| EBIT | -14.86M | -11.30M | -10.18M | -9.25M | -7.87M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.20 | -1.07 | -1.03 | -0.86 | -0.74 |
| Normalized Basic EPS | -0.75 | -0.67 | -0.64 | -0.54 | -0.46 |
| EPS Diluted | -1.20 | -1.07 | -1.03 | -0.86 | -0.74 |
| Normalized Diluted EPS | -0.75 | -0.67 | -0.64 | -0.54 | -0.46 |
| Average Basic Shares Outstanding | 13.09M | 11.87M | 11.06M | 11.05M | 11.01M |
| Average Diluted Shares Outstanding | 13.09M | 11.87M | 11.06M | 11.05M | 11.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |